LYSOGENE More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 08-12-31 | |
| Director of Finance/CFO | - | 19-12-31 | |
Marie Trad
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Lichtlen
BRD | Director/Board Member | 56 | 18-03-31 |
Michel Picot
BRD | Director/Board Member | 72 | - |
| Chief Executive Officer | 52 | 08-12-31 |
LYSOGENE is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases.
The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).
| 1st Jan change | Capi. | |
|---|---|---|
| -14.19% | 11.52B | |
| +44.16% | 3.27B | |
| -19.90% | 2.02B | |
| -38.37% | 2.03B | |
| -30.21% | 1.44B | |
| +16.18% | 1.01B | |
| -6.11% | 719M | |
| -32.75% | 418M | |
| -52.35% | 339M |
